This document discusses fertility preservation techniques. It begins by defining ovarian reserve and discussing age-related declines in fertility. It describes medical indications for fertility preservation in cancer patients, including for both pre-pubertal and post-pubertal individuals. For pre-pubertal patients, options include ovarian tissue cryopreservation while for post-pubertal patients options are oocyte and embryo cryopreservation. The document also discusses the use of GnRH analogs to protect ovarian reserve during cancer treatment and debates the ethics of fertility preservation for social reasons like career planning. It concludes by looking to future techniques like in vitro maturation of oocytes.
Hysteroscopic surgery can effectively treat various intrauterine pathologies that cause infertility such as polyps, fibroids, adhesions, and septums. It allows for direct visualization and removal of abnormalities, improving chances for spontaneous or assisted conception. While hysteroscopy is considered the gold standard for diagnosing intrauterine issues, less invasive methods like ultrasound and HSG are usually sufficient. Routine hysteroscopy before first IVF is not recommended as it does not improve live birth rates, but may be beneficial after repeated failures. Operative hysteroscopy can significantly enhance fertility outcomes.
Progestogens in obstetrics: Which type and route???? Aboubakr Elnashar
Progestogens are used during pregnancy for threatened miscarriage, recurrent miscarriage, and prevention of preterm labor. Vaginal administration of progesterone results in targeted uterine delivery with minimal systemic effects. It increases endometrial tissue levels more than oral or injectable routes. Progestogen treatment reduces miscarriage risk by 47% for threatened miscarriage and 29% for recurrent miscarriage. For preterm labor prevention in singletons, vaginal progesterone reduces risk with a short cervix while injectable 17-OH PC works for prior preterm labor. In twins, vaginal progesterone only helps if the cervix is short.
The Role of laparoscopy in the era of ARTDrRokeyaBegum
The advancement of new perspectives in assisted reproductive technology (ART) through the use of modern infertility evaluation technique Stillclinician needs to reassess how infertility should be best treated.
Recently the focus of treatment for infertility has shifted from systematic correction of each identified factor.
This document discusses the management of uterine fibroids. It defines fibroids as benign tumors of the myometrium. Symptoms vary and include menstrual problems, pressure symptoms, and reproductive dysfunction like infertility. Diagnosis involves imaging like ultrasound and MRI. Treatment options include expectant management for asymptomatic cases, medical treatment to relieve symptoms using drugs like progesterone or GnRH analogues, and surgical options like hysterectomy or myomectomy. Factors in surgical decision making include size and location of fibroids, desire for future fertility, and expertise of the surgeon. Myomectomy aims to preserve the uterus but carries risks of recurrence and complications in future pregnancies.
This document summarizes a review of randomized controlled trials (RCTs) and meta-analyses from 1990-2004 on factors affecting the success of embryo transfer (ET). The review identified 2 Cochrane reviews, 5 meta-analyses, and 34 RCTs. Key findings included that pregnancy and implantation rates were increased with trial transfers, ultrasound-guided ET, depositing embryos 2cm below the fundus, and applying gentle pressure to the cervix during and after ET. Soft catheters and exposure to semen around the time of ET also improved outcomes.
May occur very early on during the attachment or migration stages (No objective evidence e.g. –ve hCG)
May also occur at a later stage (+ve hCG) but process becomes disrupted
Definition: Refers to the failure of the embryo to reach a stage when an intrauterine gestational sac is recognized by ultrasonography.
Implantation failure can apply to patients undergoing ART and patients trying to conceive without any fertility treatment.
It is a separate entity from RPL
Orvieto et al - 3 failed IVF-ET cycles with good quality embryos transferred .
Zeyneloglu et al. - 3 unsuccessful IVF specifically with two embryos of high quality
Simon and Laufer - embryo & endometrium can both play an active role in RIF
Coughlan et al. suggest a more complete working definition taking into account maternal age, number of embryos transferred, and number of cycles completed.
They define RIF as the failure of clinical pregnancy after 4 good quality embryo transfers, with at least three fresh or frozen IVF cycles, and in women under the age of 40
RIF is a complex problem with a wide variety of etiologies / mechanisms/ treatment options.
Recommendations vary depending on the source of their problem. Perhaps the best and yet most complex answer is personalized medicine, a personal approach to each patient depending on her unique set of characteristics.
It would help to establish a set of standardized tests to use, in order to do a preliminary evaluation on each patient, which would then hopefully direct the approach of treatment for each individual couple.
This can be implemented when we have well designed studies that will help us to establish new protocols.
This document discusses fertility preservation techniques. It begins by defining ovarian reserve and discussing age-related declines in fertility. It describes medical indications for fertility preservation in cancer patients, including for both pre-pubertal and post-pubertal individuals. For pre-pubertal patients, options include ovarian tissue cryopreservation while for post-pubertal patients options are oocyte and embryo cryopreservation. The document also discusses the use of GnRH analogs to protect ovarian reserve during cancer treatment and debates the ethics of fertility preservation for social reasons like career planning. It concludes by looking to future techniques like in vitro maturation of oocytes.
Hysteroscopic surgery can effectively treat various intrauterine pathologies that cause infertility such as polyps, fibroids, adhesions, and septums. It allows for direct visualization and removal of abnormalities, improving chances for spontaneous or assisted conception. While hysteroscopy is considered the gold standard for diagnosing intrauterine issues, less invasive methods like ultrasound and HSG are usually sufficient. Routine hysteroscopy before first IVF is not recommended as it does not improve live birth rates, but may be beneficial after repeated failures. Operative hysteroscopy can significantly enhance fertility outcomes.
Progestogens in obstetrics: Which type and route???? Aboubakr Elnashar
Progestogens are used during pregnancy for threatened miscarriage, recurrent miscarriage, and prevention of preterm labor. Vaginal administration of progesterone results in targeted uterine delivery with minimal systemic effects. It increases endometrial tissue levels more than oral or injectable routes. Progestogen treatment reduces miscarriage risk by 47% for threatened miscarriage and 29% for recurrent miscarriage. For preterm labor prevention in singletons, vaginal progesterone reduces risk with a short cervix while injectable 17-OH PC works for prior preterm labor. In twins, vaginal progesterone only helps if the cervix is short.
The Role of laparoscopy in the era of ARTDrRokeyaBegum
The advancement of new perspectives in assisted reproductive technology (ART) through the use of modern infertility evaluation technique Stillclinician needs to reassess how infertility should be best treated.
Recently the focus of treatment for infertility has shifted from systematic correction of each identified factor.
This document discusses the management of uterine fibroids. It defines fibroids as benign tumors of the myometrium. Symptoms vary and include menstrual problems, pressure symptoms, and reproductive dysfunction like infertility. Diagnosis involves imaging like ultrasound and MRI. Treatment options include expectant management for asymptomatic cases, medical treatment to relieve symptoms using drugs like progesterone or GnRH analogues, and surgical options like hysterectomy or myomectomy. Factors in surgical decision making include size and location of fibroids, desire for future fertility, and expertise of the surgeon. Myomectomy aims to preserve the uterus but carries risks of recurrence and complications in future pregnancies.
This document summarizes a review of randomized controlled trials (RCTs) and meta-analyses from 1990-2004 on factors affecting the success of embryo transfer (ET). The review identified 2 Cochrane reviews, 5 meta-analyses, and 34 RCTs. Key findings included that pregnancy and implantation rates were increased with trial transfers, ultrasound-guided ET, depositing embryos 2cm below the fundus, and applying gentle pressure to the cervix during and after ET. Soft catheters and exposure to semen around the time of ET also improved outcomes.
May occur very early on during the attachment or migration stages (No objective evidence e.g. –ve hCG)
May also occur at a later stage (+ve hCG) but process becomes disrupted
Definition: Refers to the failure of the embryo to reach a stage when an intrauterine gestational sac is recognized by ultrasonography.
Implantation failure can apply to patients undergoing ART and patients trying to conceive without any fertility treatment.
It is a separate entity from RPL
Orvieto et al - 3 failed IVF-ET cycles with good quality embryos transferred .
Zeyneloglu et al. - 3 unsuccessful IVF specifically with two embryos of high quality
Simon and Laufer - embryo & endometrium can both play an active role in RIF
Coughlan et al. suggest a more complete working definition taking into account maternal age, number of embryos transferred, and number of cycles completed.
They define RIF as the failure of clinical pregnancy after 4 good quality embryo transfers, with at least three fresh or frozen IVF cycles, and in women under the age of 40
RIF is a complex problem with a wide variety of etiologies / mechanisms/ treatment options.
Recommendations vary depending on the source of their problem. Perhaps the best and yet most complex answer is personalized medicine, a personal approach to each patient depending on her unique set of characteristics.
It would help to establish a set of standardized tests to use, in order to do a preliminary evaluation on each patient, which would then hopefully direct the approach of treatment for each individual couple.
This can be implemented when we have well designed studies that will help us to establish new protocols.
Uterine-Sparing Surgery for Adenomyosis Prof. Aboubakr ElnasharAboubakr Elnashar
This document discusses uterine-sparing surgery for adenomyosis to improve fertility. It describes how adenomyosis can negatively impact fertility and IVF success rates. There are two types of uterine-sparing surgery discussed - complete excision (adenomyomectomy) for localized adenomyosis and partial excision (cytoreductive surgery) for diffuse adenomyosis. The techniques, indications, complications, and outcomes of these surgeries are examined, including improved fertility and pregnancy rates compared to hormonal therapies. However, risks like uterine rupture during subsequent pregnancy must be considered. Overall, the document concludes uterine-sparing surgery is a feasible option for improving fertility in qualified patients with adenomyosis, but it requires
Successful embryo implantation requires a receptive endometrium during a narrow implantation window between days 20-24 of the menstrual cycle. The endometrium undergoes changes regulated by hormones to acquire adhesion molecules and lose inhibitory components. Integrins, selectins, cadherins and cytokines play important roles in the apposition, adhesion and invasion stages of implantation by mediating interactions between the embryo and endometrium. Altered expression of these biomarkers may contribute to implantation failure and infertility.
Extending the duration of embryo culture to the blastocyst stage for assisted reproduction offers sev- eral theoretical advantages over the transfer of cleavage-stage embryos. These include 1) a higher implantation rate, 2) the opportunity to select the most viable embryo(s) for transfer
Multifetal pregnancies, especially those of higher order multiples, pose significant risks to both mother and fetuses. These risks include maternal complications such as preeclampsia and gestational diabetes as well as fetal complications like premature birth, low birth weight, and developmental impairments. Multifetal pregnancy reduction (MFPR) aims to reduce these risks by terminating one or more fetuses, leaving the remaining fetuses with improved health outcomes. While controversial, MFPR is generally considered ethically acceptable for reducing high order multiples and may provide benefits for triplet pregnancies. The procedure involves using ultrasound guidance to transvaginally inject a needle into the selected fetus between 7-12 weeks gestation.
Chromosomal abnormalities, inadequate culture conditions, and suboptimal embryo development are major factors contributing to recurrent implantation failure (RIF) after in vitro fertilization (IVF). While preimplantation genetic screening (PGS) aimed to improve outcomes by selecting chromosomally normal embryos, evidence suggests it does not increase live birth or implantation rates in RIF patients. New techniques like time-lapse imaging, metabolomics, and comprehensive chromosome screening may provide better embryo assessment but require further evaluation. Optimal culture conditions, blastocyst transfer, and assisted hatching in selected cases may help overcome challenges, but the safety and efficacy of emerging treatments should be established through randomized trials before routine use.
This document summarizes a study examining the relationship between endometrial BCL6 expression and IVF success or failure. The study found that women with low endometrial BCL6 expression (<1.4) had a 66% success rate for pregnancy through IVF, while women with high BCL6 expression (≥1.4) only had a 10% success rate. This suggests BCL6 expression may be a biomarker for predicting IVF outcomes and identifying women who may benefit more from treating endometriosis directly rather than undergoing IVF. Future studies are needed to validate these findings in other populations and examine how BCL6 expression changes after treating endometriosis.
1. The document discusses recurrent pregnancy loss (RPL), defined as three or more consecutive miscarriages. Common known causes of RPL include genetic factors, immune factors, anatomic abnormalities, and endocrine issues.
2. Several areas of uncertainty around RPL are discussed, such as the effectiveness of interventions like hCG, progesterone, anticoagulation therapy, and "tender loving care". The definition and distinction between early fetal demise and early embryonic demise is also unclear.
3. More research is needed to better understand unexplained RPL and identify potential underlying causes that current tests cannot detect. Larger randomized controlled trials of treatments and multicenter studies are needed to expand knowledge of RPL.
This document discusses endometriosis and its impact on fertility and IVF outcomes. It provides information on diagnosing and treating endometriosis, including:
- Laparoscopy is the gold standard for diagnosing endometriosis. Surgical excision of endometriomas and deep endometriosis can improve pain and fertility outcomes.
- For subfertility, treatment depends on factors like disease severity, pain levels, and reproductive plans. IVF is an option if conservative treatments fail.
- Studies show endometriosis may reduce ovarian response and increase IVF cancellation rates. However, it does not significantly impact live birth, pregnancy, or miscarriage rates compared to other infertility factors
Adenomyosis is a difficult disease to diagnose due to overlapping symptoms with other conditions like fibroids. While historically considered a disease of parous women, it is increasingly being identified in nulliparous women as well. MRI is the gold standard for diagnosis but ultrasound, especially 3D ultrasound of the junctional zone, can also provide clues. Treatment depends on patient goals and includes long acting progestins, long protocol IVF to suppress symptoms during fertility treatment, and in some cases focused ultrasound or uterine sparing surgery. More research is still needed on newer minimally invasive treatments.
Treatment of endometriosis associated infertility An evidence based approachAboubakr Elnashar
This document summarizes treatment guidelines for endometriosis-associated infertility from an evidence-based perspective. It discusses diagnosis of endometriosis through laparoscopy and histology. For treatment, it recommends surgical excision of visible endometriosis rather than expectant management. It finds no evidence supporting hormonal therapies for improving fertility in minimal-mild endometriosis. For more severe stages, it recommends operative laparoscopy. The document also reviews guidelines for IUI, IVF, and whether surgery is recommended before or after ART. It provides recommendations on treatments for endometriomas and deep infiltrating endometriosis.
This study evaluated the use of the endometrial receptivity array (ERA) test to diagnose endometrial receptivity issues in patients with repeated implantation failure (RIF). The ERA test analyzes gene expression patterns in endometrial tissue to determine if the window of implantation is receptive or non-receptive. The study found that 25.9% of RIF patients had a non-receptive diagnosis, suggesting displacement of the implantation window. For patients undergoing personalized embryo transfer based on the ERA results, pregnancy and implantation rates were 51.7% and 33.9% respectively. The study provides preliminary evidence that the ERA test may help identify endometrial issues contributing to RIF and guide treatment.
This document discusses the use of letrozole for fertility treatments. It begins with an introduction and outline on polycystic ovary syndrome (PCOS), unexplained infertility, fertility preservation for breast cancer patients, frozen embryo transfer, and decreasing ovarian hyperstimulation syndrome (OHSS). It then goes into more detail on each topic, providing evidence from randomized controlled trials, meta-analyses, and clinical guidelines that letrozole results in higher pregnancy and live birth rates compared to clomiphene citrate for PCOS and unexplained infertility. It also discusses how letrozole can be used during fertility preservation for breast cancer patients to prevent high estrogen levels. The document concludes by stating letrozole may
The document summarizes recent developments in human embryo morphology and genetic testing. It describes the historical discoveries of human oocyte and embryo development from the ancient Egyptians to modern IVF techniques. It also discusses current methods to select the best embryos through morphology assessment, preimplantation genetic testing for aneuploidy and genetic defects, analysis of mitochondrial content, and potential biomarkers in embryo culture media. The future of IVF is moving towards single euploid embryo transfers with comprehensive genetic and mitochondrial analysis to achieve the highest implantation rates.
Recurrent pregnancy loss is a significant redroductive medical problem, influencing 2%–5% of couples. ... Throughout the years, proof based medications, for example, surgical correction of uterine abnormalities or asprin and heparin for antiphospholipid syndrome have improved the results for couples with repetitive pregnancy loss.
The document discusses recurrent implantation failure (RIF) after in vitro fertilization (IVF). RIF can be caused by factors related to the embryo, endometrium, or both. Embryo factors include poor egg or sperm quality, genetic abnormalities, or developmental issues. Endometrial factors involve uterine abnormalities, thin lining, altered receptors, or immunological incompatibility. Treatments aim to improve the embryo, such as by changing stimulation protocols, or the endometrium through hysteroscopic surgery, immunotherapy, or adjusting the transfer timing. Testing includes evaluating the embryos, endometrium, cavitary abnormalities, and immunological factors to guide personalized treatment strategies for RIF patients.
Myoma uteri, also known as uterine fibroids, are benign smooth muscle tumors of the uterus that are quite common. The exact cause is unclear but they are hormonally responsive to estrogen. Symptoms vary depending on the size, position and condition of the fibroids and can include heavy menstrual bleeding, pelvic pressure and pain. Treatment options include medication, myomectomy (surgical removal of the fibroids), or hysterectomy (removal of the uterus). Investigation may involve ultrasound, MRI, or hysteroscopy to determine appropriate treatment.
Uterine fibroids are common non-cancerous tumors that can affect fertility. Submucosal fibroids that distort the uterine cavity have been shown to decrease pregnancy rates, while evidence for intramural fibroids is less clear. Treatment options include medical therapy, uterine artery embolization, hysteroscopic or laparoscopic myomectomy. Myomectomy can improve fertility outcomes, especially for submucosal fibroids, but carries risks of adhesion formation and possible increased risk of uterine rupture in future pregnancies. More research is still needed to fully understand the relationship between fibroid location, size and infertility.
Uterine-Sparing Surgery for Adenomyosis Prof. Aboubakr ElnasharAboubakr Elnashar
This document discusses uterine-sparing surgery for adenomyosis to improve fertility. It describes how adenomyosis can negatively impact fertility and IVF success rates. There are two types of uterine-sparing surgery discussed - complete excision (adenomyomectomy) for localized adenomyosis and partial excision (cytoreductive surgery) for diffuse adenomyosis. The techniques, indications, complications, and outcomes of these surgeries are examined, including improved fertility and pregnancy rates compared to hormonal therapies. However, risks like uterine rupture during subsequent pregnancy must be considered. Overall, the document concludes uterine-sparing surgery is a feasible option for improving fertility in qualified patients with adenomyosis, but it requires
Successful embryo implantation requires a receptive endometrium during a narrow implantation window between days 20-24 of the menstrual cycle. The endometrium undergoes changes regulated by hormones to acquire adhesion molecules and lose inhibitory components. Integrins, selectins, cadherins and cytokines play important roles in the apposition, adhesion and invasion stages of implantation by mediating interactions between the embryo and endometrium. Altered expression of these biomarkers may contribute to implantation failure and infertility.
Extending the duration of embryo culture to the blastocyst stage for assisted reproduction offers sev- eral theoretical advantages over the transfer of cleavage-stage embryos. These include 1) a higher implantation rate, 2) the opportunity to select the most viable embryo(s) for transfer
Multifetal pregnancies, especially those of higher order multiples, pose significant risks to both mother and fetuses. These risks include maternal complications such as preeclampsia and gestational diabetes as well as fetal complications like premature birth, low birth weight, and developmental impairments. Multifetal pregnancy reduction (MFPR) aims to reduce these risks by terminating one or more fetuses, leaving the remaining fetuses with improved health outcomes. While controversial, MFPR is generally considered ethically acceptable for reducing high order multiples and may provide benefits for triplet pregnancies. The procedure involves using ultrasound guidance to transvaginally inject a needle into the selected fetus between 7-12 weeks gestation.
Chromosomal abnormalities, inadequate culture conditions, and suboptimal embryo development are major factors contributing to recurrent implantation failure (RIF) after in vitro fertilization (IVF). While preimplantation genetic screening (PGS) aimed to improve outcomes by selecting chromosomally normal embryos, evidence suggests it does not increase live birth or implantation rates in RIF patients. New techniques like time-lapse imaging, metabolomics, and comprehensive chromosome screening may provide better embryo assessment but require further evaluation. Optimal culture conditions, blastocyst transfer, and assisted hatching in selected cases may help overcome challenges, but the safety and efficacy of emerging treatments should be established through randomized trials before routine use.
This document summarizes a study examining the relationship between endometrial BCL6 expression and IVF success or failure. The study found that women with low endometrial BCL6 expression (<1.4) had a 66% success rate for pregnancy through IVF, while women with high BCL6 expression (≥1.4) only had a 10% success rate. This suggests BCL6 expression may be a biomarker for predicting IVF outcomes and identifying women who may benefit more from treating endometriosis directly rather than undergoing IVF. Future studies are needed to validate these findings in other populations and examine how BCL6 expression changes after treating endometriosis.
1. The document discusses recurrent pregnancy loss (RPL), defined as three or more consecutive miscarriages. Common known causes of RPL include genetic factors, immune factors, anatomic abnormalities, and endocrine issues.
2. Several areas of uncertainty around RPL are discussed, such as the effectiveness of interventions like hCG, progesterone, anticoagulation therapy, and "tender loving care". The definition and distinction between early fetal demise and early embryonic demise is also unclear.
3. More research is needed to better understand unexplained RPL and identify potential underlying causes that current tests cannot detect. Larger randomized controlled trials of treatments and multicenter studies are needed to expand knowledge of RPL.
This document discusses endometriosis and its impact on fertility and IVF outcomes. It provides information on diagnosing and treating endometriosis, including:
- Laparoscopy is the gold standard for diagnosing endometriosis. Surgical excision of endometriomas and deep endometriosis can improve pain and fertility outcomes.
- For subfertility, treatment depends on factors like disease severity, pain levels, and reproductive plans. IVF is an option if conservative treatments fail.
- Studies show endometriosis may reduce ovarian response and increase IVF cancellation rates. However, it does not significantly impact live birth, pregnancy, or miscarriage rates compared to other infertility factors
Adenomyosis is a difficult disease to diagnose due to overlapping symptoms with other conditions like fibroids. While historically considered a disease of parous women, it is increasingly being identified in nulliparous women as well. MRI is the gold standard for diagnosis but ultrasound, especially 3D ultrasound of the junctional zone, can also provide clues. Treatment depends on patient goals and includes long acting progestins, long protocol IVF to suppress symptoms during fertility treatment, and in some cases focused ultrasound or uterine sparing surgery. More research is still needed on newer minimally invasive treatments.
Treatment of endometriosis associated infertility An evidence based approachAboubakr Elnashar
This document summarizes treatment guidelines for endometriosis-associated infertility from an evidence-based perspective. It discusses diagnosis of endometriosis through laparoscopy and histology. For treatment, it recommends surgical excision of visible endometriosis rather than expectant management. It finds no evidence supporting hormonal therapies for improving fertility in minimal-mild endometriosis. For more severe stages, it recommends operative laparoscopy. The document also reviews guidelines for IUI, IVF, and whether surgery is recommended before or after ART. It provides recommendations on treatments for endometriomas and deep infiltrating endometriosis.
This study evaluated the use of the endometrial receptivity array (ERA) test to diagnose endometrial receptivity issues in patients with repeated implantation failure (RIF). The ERA test analyzes gene expression patterns in endometrial tissue to determine if the window of implantation is receptive or non-receptive. The study found that 25.9% of RIF patients had a non-receptive diagnosis, suggesting displacement of the implantation window. For patients undergoing personalized embryo transfer based on the ERA results, pregnancy and implantation rates were 51.7% and 33.9% respectively. The study provides preliminary evidence that the ERA test may help identify endometrial issues contributing to RIF and guide treatment.
This document discusses the use of letrozole for fertility treatments. It begins with an introduction and outline on polycystic ovary syndrome (PCOS), unexplained infertility, fertility preservation for breast cancer patients, frozen embryo transfer, and decreasing ovarian hyperstimulation syndrome (OHSS). It then goes into more detail on each topic, providing evidence from randomized controlled trials, meta-analyses, and clinical guidelines that letrozole results in higher pregnancy and live birth rates compared to clomiphene citrate for PCOS and unexplained infertility. It also discusses how letrozole can be used during fertility preservation for breast cancer patients to prevent high estrogen levels. The document concludes by stating letrozole may
The document summarizes recent developments in human embryo morphology and genetic testing. It describes the historical discoveries of human oocyte and embryo development from the ancient Egyptians to modern IVF techniques. It also discusses current methods to select the best embryos through morphology assessment, preimplantation genetic testing for aneuploidy and genetic defects, analysis of mitochondrial content, and potential biomarkers in embryo culture media. The future of IVF is moving towards single euploid embryo transfers with comprehensive genetic and mitochondrial analysis to achieve the highest implantation rates.
Recurrent pregnancy loss is a significant redroductive medical problem, influencing 2%–5% of couples. ... Throughout the years, proof based medications, for example, surgical correction of uterine abnormalities or asprin and heparin for antiphospholipid syndrome have improved the results for couples with repetitive pregnancy loss.
The document discusses recurrent implantation failure (RIF) after in vitro fertilization (IVF). RIF can be caused by factors related to the embryo, endometrium, or both. Embryo factors include poor egg or sperm quality, genetic abnormalities, or developmental issues. Endometrial factors involve uterine abnormalities, thin lining, altered receptors, or immunological incompatibility. Treatments aim to improve the embryo, such as by changing stimulation protocols, or the endometrium through hysteroscopic surgery, immunotherapy, or adjusting the transfer timing. Testing includes evaluating the embryos, endometrium, cavitary abnormalities, and immunological factors to guide personalized treatment strategies for RIF patients.
Myoma uteri, also known as uterine fibroids, are benign smooth muscle tumors of the uterus that are quite common. The exact cause is unclear but they are hormonally responsive to estrogen. Symptoms vary depending on the size, position and condition of the fibroids and can include heavy menstrual bleeding, pelvic pressure and pain. Treatment options include medication, myomectomy (surgical removal of the fibroids), or hysterectomy (removal of the uterus). Investigation may involve ultrasound, MRI, or hysteroscopy to determine appropriate treatment.
Uterine fibroids are common non-cancerous tumors that can affect fertility. Submucosal fibroids that distort the uterine cavity have been shown to decrease pregnancy rates, while evidence for intramural fibroids is less clear. Treatment options include medical therapy, uterine artery embolization, hysteroscopic or laparoscopic myomectomy. Myomectomy can improve fertility outcomes, especially for submucosal fibroids, but carries risks of adhesion formation and possible increased risk of uterine rupture in future pregnancies. More research is still needed to fully understand the relationship between fibroid location, size and infertility.
Uterine fibroids are common non-cancerous tumors that can affect fertility. While their exact effects are still being established, submucosal fibroids which distort the uterine cavity have been shown to decrease pregnancy rates. Myomectomy surgery to remove fibroids, especially those that are submucosal, can improve fertility outcomes by halving miscarriage risks and increasing pregnancy rates to similar levels as women without fibroids. The optimal treatment depends on factors like fibroid location, size and number, as well as the patient's fertility desires.
Uterine fibroids are common non-cancerous tumors that can affect fertility. While their exact effects are still being established, submucosal fibroids which distort the uterine cavity have been shown to decrease pregnancy rates. Myomectomy surgery to remove fibroids, especially those that are submucosal, can improve fertility outcomes by halving miscarriage risks and increasing pregnancy rates to similar levels as women without fibroids. The optimal treatment depends on factors like fibroid location, size and number, as well as the patient's age and fertility desires.
Surgical Management of Genital AbnormalityUlun Uluğ
This document discusses surgical management of genital abnormalities. It finds that uterine anomalies are more common than recognized, with a prevalence of 1 in 200 in the general population. Various uterine anomalies like septate, bicornuate and arcuate uteri are associated with higher rates of spontaneous abortion, preterm delivery, infertility and other obstetric complications. Surgical treatments like hysteroscopic resection of septum can improve pregnancy outcomes in certain anomalies. Overall management depends on the type and severity of the anomaly and patient's clinical situation and desires.
This document discusses fibroids, also known as leiomyomas. It provides information on the different types of fibroids, risk factors, clinical presentation, investigations, complications, and treatment options. Fibroids are benign smooth muscle tumors that arise in the uterus and are the most common tumors and a leading cause of hysterectomy in women. They can be asymptomatic or cause symptoms like abnormal bleeding, pressure, and reproductive issues. Diagnosis involves ultrasound, MRI, or hysteroscopy. Treatment depends on factors like age, fibroid size and location, symptoms, and fertility wishes. Options include conservative monitoring, medical management to control symptoms, surgical treatments like hysteroscopic removal, myomectomy, or hysterectomy, and uterine artery e
Congenital disorders of female reproductive tract762060
This document discusses congenital malformations of the reproductive organs, including absence of the vagina, uterine malformations, and fallopian tube/ovary abnormalities. It describes various classes of uterine malformations such as bicornuate, didelphic, and septated uteruses. Women with these conditions may experience issues like infertility, recurrent pregnancy loss, pain, and abnormal bleeding. Diagnosis involves physical exams, ultrasounds, and other imaging tests. Treatment depends on the specific abnormality but may include dilation, surgery, and counseling. Pregnancy with some malformations carries higher risks of complications.